3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
10
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Melanoma
4
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Colonic Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Localized Prostate Cancer
1
Refractory or Relapsed Solid Tumors
1
Interventions
Cyclophosphamide
8
fludarabine phosphate
6
fludarabine
5
Bendamustine Hydrochloride
4
Busulfan
3
AP 1903 reagent
3
pembrolizumab
2
Tacrolimus
2
Mycophenolic Acid
2
thymoglobulin
1
pimonidazole
1
palbociclib
1
ibritumomab tiuxetan
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Rivaroxaban
1
Rituximab
1
Radiotherapy
1
Plasmalyte A
1
Pharmacogenomic Testing
1
Melphalan
1
Hydroxychloroquine
1
Etoposide
1
Dimethyl Sulfoxide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immune System Diseases
×
Hydroxychloroquine
×
Clear all
NCT02765594
2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4
Unknown
98 enrolled